Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma


Annelise M Wilhite, Sharon Wu, Joanne Xiu, Britt Kristina Erickson, Rodney Paul Rocconi, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, John Wallbillich, Ira Seth Winer, Matthew A. Powell, Wolfgang Michael Korn, Nathaniel L. Jones

Background: Uterine carcinosarcoma (UCS) is subtype of endometrial cancer (EC) with aggressive behavior and poor prognosis. UCS has not traditionally been included in EC clinical trials and treatment options are limited. Immune-oncology (IO) therapy has shown promise UCS, but it is unknown which patients benefit most. We sought to identify immunogenic markers in UCS and explore treatment response to IO therapy.

Download Publication